To date, several ICIs have been approved by regulatory agencies for the treatment of advanced NSCLC, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, durvalumab), and the CTLA-4 inhibitor ipilimumab (8). This evidence concerns the gene CD274 and non-small cell lung carcinoma.